口服中药治疗儿童脑性瘫痪的系统评价与核心用药探索
结果显示,中药组在有效率(RR: 1.21, 95% CI: 1.13-1.30, p<0.001)和粗大运动功能(SMD: 1.49; 95% CI: 1.33-1.65, p<0.001)上均优于对照组。核心中药涉及免疫调节与代谢系统,但研究设计存在偏倚风险。
要点
- 口服中药联合标准治疗可提高脑瘫患儿有效率及粗大运动功能。
- 核心中药包括甘草、茯苓、白芍、熟地黄、黄芪、当归。
- 亚组分析显示痉挛型或混合型、轻中度患儿获益更明显。
核心结论
- 口服中药对儿童脑性瘫痪管理可能有积极作用,但研究设计的潜在偏倚应改进。
主要发现
- 中药组有效率改善的RR为1.21(95% CI: 1.13-1.30, p<0.001, I2=32%)。
- 中药组粗大运动功能改善的SMD为1.49(95% CI: 1.33-1.65, p<0.001, I2=92%)。
- 试验序贯分析显示结果具有适当统计功效。
- 亚组分析显示使用核心中药、较长治疗时间、痉挛型或混合型、轻中度患儿同质性更好。
关键数值与推荐
- 核心中药包括Glycyrrhiza uralensis Fisch. Ex DC.、Poria cocos (Schw.) Wolf、Paeonia lactiflora Pall.、processed Rehmannia glutinosa (Gaertn.) DC.、Astragalus mongholicus Bunge、Angelica sinensis (Oliv.) Diels,作用涉及免疫调节与代谢系统。
临床怎么用
- 临床可考虑在标准治疗基础上联合口服中药以改善脑瘫患儿有效率和运动功能。
- 针对痉挛型或混合型、轻中度患儿,或使用核心中药及较长疗程时可能获益更明显。
局限性
- 研究设计存在潜在偏倚,需改进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chinese herbal medicine (CHM) taken orally is frequently utilized to enhance functional ability and independence in cerebral palsy (CP); nonetheless, there is a lack of current evidence regarding the efficacy of oral CHM in treating CP. Additionally, the general complexities of CHM prescriptions often obscure the underlying mechanisms. Our study aims to assess the efficacy of oral CHM in treating CP, a meta-analysis will be conducted on randomized clinical trials (RCTs). MATERIALS AND METHODS: We searched Cochrane Library, PubMed, Embase, Scopus, PubMed Central, ClinicalTrials.gov, and China National Knowledge Infrastructure (CNKI), from 1990 to 2022. The primary outcome was the improvement in Effectiveness rate (ER). The secondary outcome was the improvement of motor function (GMFM). Subgroup analysis and trial sequential analysis (TSA) were conducted to confirm results consistency. Core CHMs were investigated through system pharmacology analysis. RESULTS: Seventeen RCTs were analyzed, in which CHMs with Standard treatment (ST) were compared to ST alone. All participants were aged <11 years. More participants in the CHM group achieved prominent improvement in ER (RR: 1.21, 95% CI: 1.13-1.30, p-value < 0.001, I2 = 32%) and higher GMFM improvement (SMD: 1.49; 95% CI: 1.33-1.65, p-value < 0.001, I2 = 92%). TSA also showed similar results with proper statistical power. Core CHMs, such as Glycyrrhiza uralensis Fisch. Ex DC., Poria cocos (Schw.) Wolf, Paeonia lactiflora Pall., processed Rehmannia glutinosa (Gaertn.) DC., Astragalus mongholicus Bunge, and Angelica sinensis (Oliv.) Diels, exerted effects on immune modulation and metabolism systems. The subgroup analysis showed participants using core CHMs or longer CHM treatment duration, and studies enrolling CP with spastic or mixed type, or mild-to-moderate severity had better outcomes in CHM groups with less heterogeneity. CONCLUSION: CHMs may have a positive impact on managing pediatric CP; however, the potential bias in study design should be improved. SYSTEMATIC REVIEW REGISTRATION: Identifier CRD42023424754.
引用
- Huang YY, Cheng YY, Chen HY, et al. Chinese herbal medicine for the treatment of children with cerebral palsy: a meta-analysis of randomized controlled trials with core herbs exploration. Front Pharmacol. 2025. PMID: 40078275. doi:10.3389/fphar.2025.1500095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。